Advertisement

Immunosuppressive Therapy

  • Mark F. Prummel
Part of the Endocrine Updates book series (ENDO, volume 14)

Abstract

On the premise that Graves’ ophthalmopathy is an autoimmune disorder, immunosuppressive therapy has become the mainstay of treatment if the disease is severe enough. The pathogenesis of Graves’ ophthalmopathy is not yet clear and the relative importance of cellularversushumoral immune responses against the orbital tissues is uncertain. This is one of the reasons that targeted immunomodulating therapies have not been used in this disease. Therefore, most patients with moderate to severe eye disease are treated with general anti-inflammatory and immunosuppressive treatments like corticosteroids and/or orbital irradiation. In the first part of this chapter the advantages and disadvantages of these and other currently used therapies will be discussed. In the second part, possible future developments involving newer forms of immunomodulation will be mentioned.

Keywords

Rheumatoid Arthritis Islet Transplantation Oral Prednisone Experimental Allergic Encephalomyelitis rheumatOid arthritiS 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marcocci C, Pinchera A, Prummel MF, Wiersinga WM. Immunosuppressive management of Graves’ ophthalmopathy. In: Prummel MF (Ed.) Recent developments in Graves’ ophthalmopathy. Kluwer Academic Publishers. Boston: 2000; 101–113.CrossRefGoogle Scholar
  2. 2.
    Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med 1993; 329:1468–1475.PubMedCrossRefGoogle Scholar
  3. 3.
    Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: Reality and perspectives. Endocr Rev 2000; 21:168–199.PubMedCrossRefGoogle Scholar
  4. 4.
    Marcocci C, Tanda ML, Manetti L, et al. Intravenous and oral glucocorticoid therapy in patients with severe Graves’ ophthalmopathy: Results of a randomized, single-blind, prospective study [abstract]. J Endocrinol Invest 1999; 22(Suppl. 6):104.Google Scholar
  5. 5.
    Wiersinga WM, Prummel MF. An evidence-based approach to the treatment of Graves’ opthalmopathy. Endocrinol Metab Clin NA 2000; 29:297–319.CrossRefGoogle Scholar
  6. 6.
    Prummel MF, Mounts MP, Blank L, Berghout A, Koomeef L, Wiersinga WM. Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 1993; 342: 949–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Prummel MF, Mounts MPh, Berghout Aet al.Prednisone and Cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 1989; 321:1353–1359.PubMedCrossRefGoogle Scholar
  8. 8.
    Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107–116.PubMedCrossRefGoogle Scholar
  9. 9.
    Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor 13. Lancet 1998; 351:184–185.PubMedCrossRefGoogle Scholar
  10. 10.
    Kahaly G, Pitz S, Muller-Forell W, Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves’ ophthalmopathy. Clin Exp Immunol 1996; 106:197–202.PubMedCrossRefGoogle Scholar
  11. 11.
    Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, Fallah P. Intravenous immunoglobulin versus corticosteroid in treatment of Graves’ ophthalmopathy. Thyroid 1997; 7:579–585.PubMedCrossRefGoogle Scholar
  12. 12.
    Picton P, Chisholm M. Aseptic meningitis associated with high dose immunoglobulin: case report. Br Med J 1997; 315:1203–1204.CrossRefGoogle Scholar
  13. 13.
    Yu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD, Biswas RM. Hepatitits C transmission associated with intravenous immunoglobulins. Lancet 1997; 345:1173–1174.CrossRefGoogle Scholar
  14. 14.
    Bartalena L, Marcocci C, Chiovato Let al.Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56:1139.PubMedCrossRefGoogle Scholar
  15. 15.
    Marcocci C, Bartalena L, Panicucci Met al.Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves’ ophthalmopathy: a comparative study. Clin Endocrinol 1987; 27:33.CrossRefGoogle Scholar
  16. 16.
    Gerding MN, Van der Zant FM, Van Royen EAet al.Octreotide-scintigraphy is a disease activity parameter in Graves’ ophthalmopathy. Clin Endocrinol 1999; 50:373–379.CrossRefGoogle Scholar
  17. 17.
    Wiersinga WM, Gerding MN, Prummel MF, Krenning EP. Octreotide scintigraphy in thyroidal and orbital Graves’ disease. Thyroid 1998; 8: 433–436.PubMedCrossRefGoogle Scholar
  18. 18.
    Chang TC, Kao SCS, Huang KM. Octreotide and Graves’ ophthalmopathy and pretibial myxoedema. Br Med J 1992; 304:158.CrossRefGoogle Scholar
  19. 19.
    Kung AWC, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves’ ophthalmopathy. Thyroid 1996; 6:381.PubMedCrossRefGoogle Scholar
  20. 20.
    Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 1995; 42:571.CrossRefGoogle Scholar
  21. 21.
    Krassas GE, Kaltsas T, Dumas A, Pontikides N, Tolis G. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997; 136:416.PubMedCrossRefGoogle Scholar
  22. 22.
    Borel JF, Hiestand PC. Immunomodulation: particular pesrpectives. Transpl Proc 1999; 31:1464–1471.CrossRefGoogle Scholar
  23. 23.
    Mihatchi MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49:356–363.Google Scholar
  24. 24.
    Prummel MF, Terwee CB, Gerding MN, Blank L, Mourits MPh, Dekker FW, Wiersinga WM. A randomized placebo-controlled study on radiotherapy for mild Graves’ ophthalmopathy: effects on clinical severity and quality of life. [abstract] 12th International Thyroid Congress. Oct 22–27, 2000; Kyoto, Japan.Google Scholar
  25. 25.
    Mourits Mph, Kempen-Hartveld M van, Garcia Garcia B, Koppeschaar HPF, Tick L, Terwee CB. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet 2000; 355:1505–1509.CrossRefGoogle Scholar
  26. 26.
    Kahaly G, SchrezenmeirJKrause U, Schweikert B, Meuer S, Muller W. Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986; 16:415.PubMedCrossRefGoogle Scholar
  27. 27.
    Glinoer D, Etienne-Decerf J, Schrooven Met al.1986 Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves’ ophthalmopathy. Acta Endocrinol (Copenh) 1986; 111:30.Google Scholar
  28. 28.
    De Rosa G, Menichella G, Della Set al.Plasma exchange in Graves’ ophthalmopathy. Prog Clin Biol Res 1990; 337:321.PubMedGoogle Scholar
  29. 29.
    Kahaly G, Lieb W, Muller-Forell Wet al.Ciamexone in endocrine orbitopathy: a randomized, double-blind, placebo-controlled study. Acta Endocrinol (Copenh) 1990; 122:13.Google Scholar
  30. 30.
    Perros P, Weightman DR, Crombie AL, Kendall-Taylor P. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh) 1990; 122:8Google Scholar
  31. 31.
    Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol 1998; 49:21–28.CrossRefGoogle Scholar
  32. 32.
    Rogvi-Hansen B, Perrild H, Christensen T, Detmar S, Siersbaek-Nielsen K, Hansen J. Acupuncture in the treatment of Graves’ ophthalmopathy. A blinded randomized study. Acta Endocrinol (Copenh) 191; 124:143.Google Scholar
  33. 33.
    Prummel MF, Wiersinga WM, Mourits Mph. Assessment of disease activity of Graves’ ophthalmopathy. In: Prummel MF (ed), Recent developments in Graves’ ophthalmopathy. Boston: Kluwer Academic Publishers 2000: 59–80CrossRefGoogle Scholar
  34. 34.
    Mourits MPh, Rose GE, Garrity JA, Nardi M, Matton G, Koornneef L. Surgical management of Graves’ ophthalmopathy. In: Prummel MF (Ed) Recent developments in Graves’ ophthalmopathy. Boston: Kluwer Academic Publishers 2000:133–169.CrossRefGoogle Scholar
  35. 35.
    Schiff M. Emerging treatments for Rheumatoid Arthritis. Am J Med 1997; 102 (Suppl. 1 A):11 S-15S.Google Scholar
  36. 36.
    Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Int Med 1999; 131:768–774.PubMedGoogle Scholar
  37. 37.
    Claridge KG, Ghabrial R, Davis G, Tomlinson M, Goodman S, Harrad RA, Potts MJ. Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease. Eye 1997; 11:717–722.PubMedCrossRefGoogle Scholar
  38. 38.
    Bartalena L, Marcocci C, Pinchera A. Editrial: Cytokine antagonists: New ideas for the management of Graves’ ophthalmopathy.JClin Endocrinol Metab 1996; 81:446–448.CrossRefGoogle Scholar
  39. 39.
    Prummel MF, Wiersinga WM. Immunomodulatory treatment of Graves’ ophthalmopathy. Thyroid 1998; 8:545–548.PubMedCrossRefGoogle Scholar
  40. 40.
    Heufelder AE, Weetman AP, Ludgate M, Bahn RS. Pathogenesis of Graves’ ophthalmopathy. In: Prummel MF (Ed) Recent developments in Graves’ ophthalmopathy. Boston: Kluwer Academic Publishers 2000:15–37.CrossRefGoogle Scholar
  41. 41.
    Schwartz RS. The new immunology - The end of immunosuppressivee drug therapy? N Engl J Med 1999; 340:1754–1756.PubMedCrossRefGoogle Scholar
  42. 42.
    Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355:735–740.PubMedCrossRefGoogle Scholar
  43. 43.
    Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000; 51:207–229.PubMedCrossRefGoogle Scholar
  44. 44.
    Jorgensen C, Apparailly F, Sany J. Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? Ann Rheum Dis 1999; 58:136–141.PubMedCrossRefGoogle Scholar
  45. 45.
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldman M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354:1932–1939.PubMedCrossRefGoogle Scholar
  46. 46.
    Bell S, Kamm MA. Antibodies to tumour necrosis factor a as treatment for Crohn’s disease. Lancet 2000; 355:858–857.PubMedCrossRefGoogle Scholar
  47. 47.
    Van Deventer SJH. Immunomodulation of Crohn’s disease. In: Tathman CG (Ed.): Biologic and gene therapy for autoimmune disease. Curr Dir Autoimmun Basel, Karger: 2000 (2):150–166.CrossRefGoogle Scholar
  48. 48.
    Shapiro AMJ, Lakey JRT, Ryan EAet al.Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230–238.PubMedCrossRefGoogle Scholar
  49. 49.
    Robertson RP. Successful islet transplantation for patients with diabetes - fact or fantasy? N Engl J Med 2000; 343:289–290.PubMedCrossRefGoogle Scholar
  50. 50.
    St Clair EW. Interleukin-10: Therapeutic prospects in rheumatoid arthritis. In: Tathman CG (Ed.): Biologic and gene therapy for autoimmune disease. Curr Dir Autoimmun Basel, Karger: 2000 (2):129–149.Google Scholar
  51. 51.
    Tan GH, Dutton CM, Bahn RS. Interleukin-1 receptor antagonist and soluble interleukin-1 receptor inhibit interleukin-linduced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1996; 81:449–452.PubMedCrossRefGoogle Scholar
  52. 52.
    Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rhem Dis 1999; 58 (Suppl. I):196–198.Google Scholar
  53. 53.
    Kim YS, Maslinski W, Zheng XX, Schachter AD, Strom TB. Immunoglobulincytokine fusion molecules: The new generation of immunomodulating agents. Transpl Proc 1998; 30:4031–4036.CrossRefGoogle Scholar
  54. 54.
    Dick AD, Isaacs JD. Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium. Br J Ophthalmol 1999; 83:1230–1234.PubMedCrossRefGoogle Scholar
  55. 55.
    Edwards CK. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory disease. Ann Rheum Dis 1999; 58 (Suppl. I):173–181.Google Scholar
  56. 56.
    Levi M, ten Cate H, Bauer KAet al.Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93:114–120.PubMedCrossRefGoogle Scholar
  57. 57.
    Nagy Z, Sipka R, Ocsovszki I, Balogh A, Mandi Y. Suppressive effect of pentoifylline on natural killer cell activity; experimental and clinical studies. Arch Pharmacol 1999; 359:228–234.CrossRefGoogle Scholar
  58. 58.
    Balazs C, Kiss E, Vamos A, Molnar I, Farid NR. Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO): a pilot study. J Clin Endocrinol Metab 1997; 82:1999–2002.PubMedGoogle Scholar
  59. 59.
    Woessner JF. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann NY Acad Sci 1999; 878:388–403.PubMedCrossRefGoogle Scholar
  60. 60.
    De B, Natchus MG, Cheng Met al.The next generation of MMP inihibitors. Ann NY Acad Sci 1999; 878:40–60.PubMedCrossRefGoogle Scholar
  61. 61.
    Dekkers PEP, Lauw FN, Ten Hove T, Te Velde AA, Lumley P, Bechere D, Van Deventer SJH, Van der Poll T. The effect of metalloproteinase inihibitor (GI5402) on Tumor Necrosis Factor-a (TNF-a) and TNF-a Receptors during human endotoxemia. Blood 1999; 94:2252–2258.PubMedGoogle Scholar
  62. 62.
    Bright JJ, Du C, Coon M, Sriram S, Klaus SJ. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12 mediated Thl differnetiation: An effect of the novel anti-inflammatory drug Lysofylline.JImmunol 1998; 161:7015–7022.PubMedGoogle Scholar
  63. 63.
    Coon ME, Diegel M, Leshinsky N, Klaus SJ. Selective pharmacologic inhibition of murine and human IL-12-dependent Thl differentiation and IL-12 signalling. J Immunol 1999; 163:6567–6574.PubMedGoogle Scholar
  64. 64.
    Karp CL, Biron CA, Irani DN. Interferon 13 in multiple sclerosis: is IL-12 suppression the key? Immunol Today 2000; 21:24–28.PubMedCrossRefGoogle Scholar
  65. 65.
    Gerding MN, Terwee CB, Dekker FW, Koomneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 1997; 7: 885–889.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Mark F. Prummel
    • 1
  1. 1.Department of Endocrinology & Metabolism, Academic Medical CenterUniversity of AmsterdamThe Netherlands

Personalised recommendations